Quantbot Technologies LP Acquires New Holdings in 10x Genomics, Inc. (NASDAQ:TXG)

Quantbot Technologies LP bought a new position in 10x Genomics, Inc. (NASDAQ:TXG) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 71,429 shares of the company’s stock, valued at approximately $1,026,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Counterpoint Mutual Funds LLC acquired a new stake in 10x Genomics during the 4th quarter worth $742,000. Signaturefd LLC increased its holdings in shares of 10x Genomics by 424.6% in the fourth quarter. Signaturefd LLC now owns 1,794 shares of the company’s stock worth $26,000 after acquiring an additional 1,452 shares in the last quarter. Commonwealth Equity Services LLC acquired a new stake in shares of 10x Genomics during the fourth quarter worth about $146,000. Swiss National Bank lifted its holdings in shares of 10x Genomics by 1.5% during the 4th quarter. Swiss National Bank now owns 188,400 shares of the company’s stock valued at $2,705,000 after purchasing an additional 2,700 shares in the last quarter. Finally, Wealthfront Advisers LLC acquired a new position in shares of 10x Genomics in the 4th quarter valued at approximately $4,418,000. 84.68% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of 10x Genomics in a report on Saturday. Stifel Nicolaus cut their price objective on shares of 10x Genomics from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. UBS Group reduced their target price on shares of 10x Genomics from $20.00 to $14.00 and set a “neutral” rating for the company in a research note on Thursday, February 13th. Canaccord Genuity Group dropped their price target on 10x Genomics from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. Finally, Morgan Stanley reduced their price objective on 10x Genomics from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. One analyst has rated the stock with a sell rating, nine have given a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $20.21.

10x Genomics Trading Down 6.2 %

NASDAQ TXG opened at $9.75 on Wednesday. The company has a market cap of $1.19 billion, a PE ratio of -6.41 and a beta of 1.93. 10x Genomics, Inc. has a 12 month low of $9.27 and a 12 month high of $38.49. The stock has a 50 day moving average of $12.46 and a 200-day moving average of $15.30.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. As a group, sell-side analysts predict that 10x Genomics, Inc. will post -1.43 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Benjamin J. Hindson sold 4,573 shares of 10x Genomics stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $11.07, for a total transaction of $50,623.11. Following the completion of the sale, the insider now owns 335,324 shares of the company’s stock, valued at approximately $3,712,036.68. The trade was a 1.35 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Alan Mateo purchased 40,000 shares of the stock in a transaction on Friday, February 21st. The stock was bought at an average cost of $11.14 per share, for a total transaction of $445,600.00. Following the completion of the acquisition, the director now owns 61,691 shares in the company, valued at approximately $687,237.74. This trade represents a 184.41 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 10.03% of the company’s stock.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.